| Deborah Elaine Sellmeyer, MD | |
|
300 Pasteur Dr, Stanford, CA 94305-2200 | |
| (650) 723-4000 | |
| Not Available |
| Full Name | Deborah Elaine Sellmeyer |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 33 Years |
| Location | 300 Pasteur Dr, Stanford, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225095755 | NPI | - | NPPES |
| 289861600 | Medicaid | MD | |
| 0A5439300 | Medicaid | CA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stanford Health Care | Stanford, CA | Hospital |
| Community Hospital Of The Monterey Peninsula | Monterey, CA | Hospital |
| Stanford Health Care - Valleycare | Pleasanton, CA | Hospital |
| Peninsula Medical Center | Burlingame, CA | Hospital |
| El Camino Hospital | Mountain view, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stanford Health Care | 6709797491 | 2572 |
News Archive
AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
Rheumatology patients using antitumor necrosis factor treatment should be given sun exposure education to reduce their risk for skin cancer, say Irish researchers.
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
A new study, conducted by a team of researchers from the University of California, San Diego, has identified how the environment surrounding a tumor can stimulate metastatic behavior in the individual cancer cells. Researchers found that the tumor cells activate a particular set of genes and begin to form blood vessel-like structures when they are confined in a densely packed environment.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 9 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
Rheumatology patients using antitumor necrosis factor treatment should be given sun exposure education to reduce their risk for skin cancer, say Irish researchers.
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
A new study, conducted by a team of researchers from the University of California, San Diego, has identified how the environment surrounding a tumor can stimulate metastatic behavior in the individual cancer cells. Researchers found that the tumor cells activate a particular set of genes and begin to form blood vessel-like structures when they are confined in a densely packed environment.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 9 days ago
| Entity Name | Lpch Medical Group Div Of Lucile |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417907940 PECOS PAC ID: 0840298543 Enrollment ID: O20061113000232 |
News Archive
AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
Rheumatology patients using antitumor necrosis factor treatment should be given sun exposure education to reduce their risk for skin cancer, say Irish researchers.
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
A new study, conducted by a team of researchers from the University of California, San Diego, has identified how the environment surrounding a tumor can stimulate metastatic behavior in the individual cancer cells. Researchers found that the tumor cells activate a particular set of genes and begin to form blood vessel-like structures when they are confined in a densely packed environment.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Deborah Elaine Sellmeyer, MD 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 | Deborah Elaine Sellmeyer, MD 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 |
News Archive
AbbVie today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being developed in partnership with Genentech and Roche, has been granted Breakthrough Therapy Designation by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.
Rheumatology patients using antitumor necrosis factor treatment should be given sun exposure education to reduce their risk for skin cancer, say Irish researchers.
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
A new study, conducted by a team of researchers from the University of California, San Diego, has identified how the environment surrounding a tumor can stimulate metastatic behavior in the individual cancer cells. Researchers found that the tumor cells activate a particular set of genes and begin to form blood vessel-like structures when they are confined in a densely packed environment.
A review of US hospitals indicates a lack of implementation of important practices to reduce readmission rates among patients with heart failure and acute myocardial infarction, report researchers.
› Verified 9 days ago
Prista Charuworn, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 300 Pasteur Dr, Alway Build M211, Mc 5187, Stanford, CA 94305 Phone: 650-723-6661 | |
Yu Kuang Lai, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Andrea Lorenze, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Drive, Lane 154, Stanford, CA 94305 Phone: 650-723-6661 Fax: 650-498-6205 | |
Audra Horomanski, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 Fax: 650-498-6205 | |
Meghan Brady Marmor, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Lauren Michelle Ulsh, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Ann M Chen, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, A149, Mc5202, Stanford, CA 94305 Phone: 650-725-3376 Fax: 650-723-8305 |